| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 87063-0045-21 | 87063-0045 | PREDNISONE | PREDNISONE | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec 3, 2025 | In Use | |
| 00069-1307-10 | 00069-1307 | epoetin alfa-epbx | RETACRIT | 4000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Jun 18, 2018 | In Use | ||
| 87063-0045-30 | 87063-0045 | PREDNISONE | PREDNISONE | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec 3, 2025 | In Use | |
| 69339-0172-03 | 69339-0172 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 24, 2022 | In Use | |
| 16729-0426-05 | 16729-0426 | GEMCITABINE | GEMCITABINE | 100.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Aug 6, 2018 | In Use | |
| 69339-0172-01 | 69339-0172 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 27, 2025 | In Use | |
| 69339-0172-05 | 69339-0172 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 27, 2025 | In Use | |
| 21695-0307-15 | 21695-0307 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb 26, 1974 | In Use | |
| 50742-0387-01 | 50742-0387 | Estrogens, conjugated | Estrogens, conjugated | 0.3 mg/1 | Hormonal Therapy | Estrogen | Oral | Oct 16, 2025 | In Use | ||
| 00310-0720-10 | 00310-0720 | Fulvestrant | Faslodex | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Nov 1, 2010 | In Use | ||
| 70518-1585-03 | 70518-1585 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 1, 2023 | In Use | |
| 70518-1585-02 | 70518-1585 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 3, 2021 | In Use | |
| 50742-0387-10 | 50742-0387 | Estrogens, conjugated | Estrogens, conjugated | 0.3 mg/1 | Hormonal Therapy | Estrogen | Oral | Oct 16, 2025 | In Use | ||
| 00404-9805-05 | 00404-9805 | Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 4.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intralesional, Intramuscular, Intravenous, Soft Tissue | Dec 9, 2024 | In Use | |
| 25021-0230-02 | 25021-0230 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Aug 15, 2014 | In Use | |
| 87063-0045-90 | 87063-0045 | PREDNISONE | PREDNISONE | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec 3, 2025 | In Use | |
| 70518-1585-06 | 70518-1585 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 1, 2025 | In Use | |
| 50742-0388-01 | 50742-0388 | Estrogens, conjugated | Estrogens, conjugated | 0.45 mg/1 | Hormonal Therapy | Estrogen | Oral | Oct 16, 2025 | In Use | ||
| 25021-0230-05 | 25021-0230 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Aug 15, 2014 | In Use | |
| 50742-0388-10 | 50742-0388 | Estrogens, conjugated | Estrogens, conjugated | 0.45 mg/1 | Hormonal Therapy | Estrogen | Oral | Oct 16, 2025 | In Use | ||
| 43598-0541-25 | 43598-0541 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | May 22, 2017 | In Use | |
| 49999-0153-21 | 49999-0153 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb 9, 2012 | In Use | |
| 00591-4390-96 | 00591-4390 | Mifepristone | Mifepristone | 300.0 mg/1 | Hormonal Therapy | Antiprogestin | Cortisol Receptor Blocker | Oral | Jan 19, 2024 | In Use | |
| 70518-3512-00 | 70518-3512 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sep 7, 2022 | In Use | |
| 00024-5840-01 | 00024-5840 | ziv-Aflibercept | Zaltrap | 100.0 mg/4mL | Chemotherapy | Recombinant Fusion Protein | VEGF-IgG1 | Intravenous | Aug 3, 2012 | In Use |
Found 12159 results — Export these results
Home